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ABSTRACT
The aim of the study was to investigate the course of objective memory impairment in non-demented subjects who
attended a memory clinic and to test predictors of outcome. Non-demented subjects (N  74) were included when
they were older than 40 years and had a baseline score on the delayed recall of a word learning test below the tenth
percentile. Subjects with memory impairment due to known somatic or neurological causes were excluded. The
subjects were reassessed after 2 and 5 years. At the 5-year follow-up, 42% of the subjects had no memory impairment,
19% of the subjects had memory impairment without dementia, and 39% of the subjects had Alzheimer type
dementia (AD). Predictors at baseline of reversible memory impairment in a multivariate analysis were age, scores on
theMMSE and delayed recall, and the degree of functional impairment. Predictors at baseline of AD in a multivariate
analysis were age and the score on the MMSE. The apolipoprotein E genotype and the presence of depression at
baseline were not predictors of outcome. The positive predictive value was 72% for reversible memory impairment
and 81% for AD. Memory impairment is often reversible and therefore its presence alone is not sucient to consider
subjects as preclinically demented. Predictive accuracy can be increased by including simple measures such as age, the
scores on the MMSE and delayed recall, and the degree of functional impairment. Copyright# 2000 John Wiley &
Sons, Ltd.
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Objective memory impairment in non-demented
elderly individuals is an important risk factor for
Alzheimer-type dementia (AD) (Bowen et al., 1997;
Linn et al., 1995), but cognitive impairment may
also be reversible (Alexopoulos et al., 1993;
O’Connor et al., 1990). While several studies have
investigated the relation between subjective or
objective memory impairment and subsequent
dementia (Bowen et al., 1997; Coria et al., 1995;
O’Brien et al., 1992), there have been no studies on
how often objective memory impairment in non-
demented subjects is reversible and on factors that
are associated with the reversibility of memory
impairment. It is important to distinguish subjects
with reversible memory impairment from those
who are at high risk for AD, because high-risk
subjects may be candidates for treatment with
drugs that are becoming available for AD. In
addition, the caregivers of these patients may
benefit from counselling on how to handle the
cognitive impairment of their partners.
The aim of the present longitudinal study was to
investigate the course of memory impairment and
to identify predictors of outcome. Outcome was
defined as reversible memory impairment, persist-
ent memory impairment without dementia, or AD.
We also developed post-hoc decision rules that can
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be used in clinical practice to predict outcome. We
selected variables that have been demonstrated to
be associated with an increased risk for AD or
cognitive decline in non-demented elderly subjects,
e.g. the severity of the memory impairment (Jacobs
et al., 1995; Linn et al., 1995), age (Ott et al., 1998),
the apolipoprotein E (apoE)-e4 allele (Coria et al.,
1995; Petersen et al., 1995; Slooter et al., 1998), the
score on the Mini-Mental State Examination
(MMSE) (Braekhus et al., 1995), and the degree
of interference that cognitive impairment has on
the activities of daily living (Brayne et al., 1997).
We also selected depression as a predictor because
depression may cause cognitive impairment that it
reversible after improvement of the depression
(Alexopoulos et al., 1993; Hill et al., 1992).
METHODS
Subjects
The patients were selected from the Maastricht
Memory Clinic, a university-aliated outpatient
clinic for subjects with cognitive impairment
(Verhey et al., 1993). All patients complained
about memory dysfunction and were referred by a
general practitioner (51%), a neurologist (27%), or
a psychiatrist (22%). Subjects were included when
they were older than 40 years and when they had
memory impairment. Memory impairment was
defined as an impairment on the delayed recall of
a word learning test because several studies indi-
cated that impairment on the delayed recall in
particular is predictive of subsequent dementia
(Almkvist et al., 1998; Bowen et al., 1997; Linn et al.,
1995; Tierney et al., 1996). Impairment was defined
as a score below the 10th percentile because this cut-
o is commonly used in clinical practice and is
similar to the cut-o used in criteria of mild cogni-
tive impairment (Levy, 1994; Smith et al., 1996).
This definition of memory impairment excluded
most subjects with age-related cognitive decline
(ARCD) (American Psychiatric Association, 1994),
because the memory impairment was outside the
normal limits given the person’s age. We excluded
subjects with dementia, a score on the MMSE
below 24, a score on the Global Deterioration Scale
(GDS) (Reisberg et al., 1982) higher than 3, severe
sensory impairment, psychosis, panic disorder,
post-traumatic stress disorder, bipolar disorder, or
cognitive problems in relation to cerebro-vascular
events, neurodegenerative diseases (e.g. Parkinson’s
disease), brain neoplasm, head trauma, drug
intoxication, alcohol abuse, hypothyroid or hyper-
thyroid function, or vitamin deficiency. The study
cohort consisted of 74 subjects. After the study was
explained to them, subjects gave their written
informed consent.
Baseline assessment and clinical diagnosis
All subjects underwent a standardized assess-
ment at baseline which included a detailed history
provided by the patient and a significant other, a
psychiatric, neurological, and physical examina-
tion, appropriate laboratory tests, a neuropsycho-
logical assessment, and neuroimaging as described
elsewhere (Verhey et al., 1993). In addition, the
MMSE (Folstein et al., 1975), as a measure of
global cognitive impairment, the GDS (Reisberg
et al., 1982), which is a scale for staging levels of
cognitive impairment, the Hamilton Depression
Rating Scale-17 items (HDRS) (Hamilton, 1960),
and the Blessed Dementia Rating Scale (BDRS)
part I (Blessed et al., 1968) were administered.
From the BDRS we used the total score on the first
11 items as a measure of impairment in functioning
in daily living (BDRS-DL). Psychiatric diagnoses
were made according to DSM-IV criteria (Amer-
ican Psychiatric Association, 1994). Depression
was diagnosed when the subjects fulfilled the
criteria of minor or major depression. The diag-
nosis of depression was made regardless of a
possible underlying aetiology, such as bereave-
ment, co-morbid conditions or pain. Since cogni-
tive impairment in depression is associated with the
severity of the depression (Christensen et al., 1997),
we have used the term depression in the present
study to refer to subjects with a score on the HDRS
higher than 13. None of these subjects were
severely depressed, as HDRS scores were lower
than 26. All subjects were treated according to
clinical standards with no specific treatment pro-
tocol. The clinical standard treatment of depressed
subjects consisted of drug therapy and/or psycho-
therapy.
Follow-up procedure
After 2 years and 5 years the subjects were
invited for a follow-up assessment. This consisted
of a standardized questionnaire about medical
history and cognitive complaints, the MMSE, the
GDS, the HDRS, the BDRS, and a neuropsycho-
logical test protocol. The diagnoses of dementia
and AD were made according to the DSM-IV and
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NINCDS-ADRDA criteria (McKhann et al.,
1984) by a neuropsychiatrist and a neuropsycho-
logist, who were unaware of the results of the
baseline assessment and who made their diagnosis
independently of each other. If there was disagree-
ment about the clinical diagnosis, a consensus
meeting was held and if no agreement was reached
the subject was considered not demented. No
neuropsychological testing was done at follow-up
in two subjects who were demented at follow-up
because one subject was too impaired and the other
had died after the diagnosis of dementia was made
but before the neuropsychological test was carried
out. Subjects who were demented at the 2-year
follow-up were not invited for the 5-year follow-up.
When separate analyses were performed with
subjects who had completed the 5-year follow-up,
only the demented subjects were included whose
baseline assessment was at least 5 years ago.
Delayed recall measure
The delayed recall measure was selected from a
neuropsychological assessment that consisted of a
series of standard clinical tests covering the cogni-
tive domains of memory, language, attention,
praxis, executive functions, and intelligence, as
described elsewhere (Jolles, 1986; Verhey et al.,
1993). Delayed recall was tested with the Dutch
version of the Auditory Verbal Learning Test
(AVLT) (Brand and Jolles, 1985; Lezak, 1995).
Fifteen unrelated monosyllabic words were pre-
sented five times and after each presentation the
subject was asked to reproduce as many words as
possible. After 20 min, during which non-verbal
tests were performed, delayed recall was tested. If
the neuropsychologist considered that a subject
could not perform the 15-word version of the
AVLT appropriately, a 10-word version of the test
was administered (in two subjects at the 2-year
follow-up and one subject at the 5-year follow-up).
This score was multiplied by 1.5 to make it
comparable to the others. A parallel version of
the AVLT was used at follow-up.
Correction of MMSE and delayed recall for age,
sex, and education
Since the MMSE and the delayed recall scores
correlate with age, sex and education, we corrected
the scores for these variables. The correction was
based on a reference population of 1870 cognitively
normal subjects older than 40 years randomly
selected from a registry of general practitioners
(Jolles et al., 1995; van Boxtel et al., 1998). In this
population, multiple linear regression was
performed with age, sex, and education entered in
the first step, using p5 0.05 as the criterion for
remaining in the model. In the next step, non-linear
terms and interaction terms for the significant main
eects were entered. On the basis of the resulting
model, an expected test score for each subject was
calculated. This score was subtracted from the
observed score. The residue of the delayed recall
was divided by the standard deviation of the residue
in the reference population to give a z-score. A
z-score below zero indicated below average per-
formance. A z-score of ÿ1.28 or lower corresponds
with a memory performance below the tenth
percentile of the reference population. The residue
of the MMSE was added to the expected MMSE of
a subject with average age, sex, and education in
the study population (MMSE  28.2). Both the
uncorrected and corrected MMSE scores are listed
in the tables, but only the corrected MMSE scores
were used for the analyses. The MMSE score was
not available for three subjects at baseline and
these subjects were given the average MMSE score
of the study population (Small et al., 1997). We
chose to substitute the data in order to retain these
subjects in the multivariate analysis. The analysis
with and without the subjects with substituted
MMSE scores yielded similar results. The three
subjects without an MMSE score tended to be
younger (49 years versus 61 years, p  0.07) at
baseline, and had a lower GDS score (p  0.01)
compared to the subjects with an MMSE score.
The other variables at baseline (including the z-
score of the delayed recall and the HDRS score)
were not dierent between the subjects with or
without MMSE score at baseline.
ApoE genotyping
The apoE genotyping was performed with a
polymerase chain reaction (Slooter et al., 1998;
Wenham et al., 1991). Blood samples for genotyp-
ing were taken at the follow-up assessment from
1995 onwards. Therefore, no samples were avail-
able for subjects seen before 1995 or without
follow-up. One subject refused to give blood. The
apoE genotype was available for 44 subjects (70%
of the subjects who were seen at follow-up).
Compared with the subjects who were ApoE
genotyped, the subjects who were not ApoE
genotyped had a lower score on the MMSE at
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baseline (26.9 vs 28.0, p  0.01), and were more
frequently demented at follow-up (42% vs 18%,
p  0.004). On the basis of the apoE genotype we
defined a group with the apoE-e4 allele (apoE-e4)
including the genotypes e4e4 (N  3) and e3e4
(N  20), and a group without an APO-e4 allele
(apoE-4ÿ) including the genotypes e2e3 (N  2)
and e3e3 (N  19).
Statistical analysis
In groups with more than 10 subjects, contin-
uous variables were compared by means of a t-test.
In groups with 10 or fewer subjects, continuous
variables were analysed with the Mann–Whitney
test corrected for ties. This test was also used to
analyse the BDRS-DL data. Categorical data were
analysed with a Chi-square test with continuity
correction. When two or more cells had five cases
or less, the two-tailed Fisher’s exact test was
applied. Logistic regression analysis was performed
to identify variables that were predictors of out-
come. At the first step age, the presence or absence
of depression, and the scores on the BDRS-DL,
MMSE, and delayed recall were entered and with
backward step selection variables were selected that
were significantly associated with outcome. The
apoE genotype was not entered in the multivariate
analysis because the genotype was not available for
all subjects. All statistical tests were two-tailed. The
significance level was set at 0.05.
RESULTS
Of the 74 subjects included at baseline, 11 subjects
(15%) had no assessment at follow-up because they
were untraceable (N  2), refused to participate
(N  5), had died (N  3), or had multiple system
atrophy at follow-up (N  1). Twenty-seven sub-
jects (36%) had a 2-year follow-up, 33 subjects
(45%) had both a 2-year and 5-year follow-up, and
three subjects (4%) had only a 5-year follow-up.
The subjects without a follow-up assessment had
similar baseline characteristics as the subjects with
a follow-up assessment, except for the uncorrected
MMSE score (Table 1). Nineteen subjects were
demented at follow-up; they all had probable AD.
Course of memory impairment
The course of the memory impairment is shown
in Fig. 1. In the 60 subjects with a 2-year follow-up,
the memory performance had improved in 21
(35%) and remained stable in 23 (38%). Sixteen
subjects (27%) had AD at the 2-year follow-up. In
the 36 subjects with a 5-year follow-up, memory
performance had improved in 15 (42%) and
remained stable in seven (19%). Fourteen subjects
(39%) had AD at the 5-year follow-up. One of the
10 subjects (10%) who had improved at the 2-year
follow-up showed memory impairment at the
5-year follow-up. Seven of the 23 (33%) subjects
with persistent memory impairment but no demen-
Table 1. Baseline characteristics
Follow-up No follow-up p-Value
(N  63) (N  11)
Age 60.1 (10.4) 66.9 (12.8) 0.06
Education (years) 10.3 (3.0) 11.5 (3.5) 0.16
Sex male/female 34/29 5/6 0.85
HDRS 11.1 (6.3) 10.3 (6.1) 0.69
GDS 1.0
ÿ2 (%) 20 (32) 4 (36)
ÿ3 (%) 43 (69) 7 (64)
BDRS-DL 0.88 (0.71) 1.1 (1.2) 1.0
MMSE 27.4 (1.7) 26.8 (1.1) 0.03
MMSE (corrected) 27.7 (1.6) 27.4 (1.1) 0.64
Delayed recall baseline* ÿ2.0 (0.6) ÿ2.2 (0.5) 0.34
Depressed/not depressed (% depressed) 22/41 (35) 4/7 (36) 1.0
All data are mean (SD) unless specified otherwise.
*Data expressed as z-score. A z-score below zero indicates below average performance.
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tia at the 2-year follow-up showed improved
memory function at the 5-year follow-up, while
10 (42%) of these subjects remained impaired and
six (25%) had become demented.
Predictors of outcome
We classified the subjects according to the
outcome at the most recent follow-up assessment
(Table 2) because the dierences in baseline
characteristics between the groups with reversible
memory impairment, persistent memory impair-
ment, and AD at the 2-year follow-up were similar
to the dierences in baseline characteristics be-
tween these groups at the 5-year follow-up.
Compared to non-demented subjects with persist-
ent memory impairment, subjects with reversible
memory impairment had higher MMSE and
delayed recall scores at follow-up, and were less
frequently depressed at follow-up. Subjects with
reversible memory impairment had a lower age at
baseline, lower GDS and BDRS-DL scores at
baseline, and higher MMSE and delayed recall
scores at both baseline and follow-up than did the
subjects who had AD at follow-up. Subjects who
were impaired but not demented at follow-up were
younger and had lower GDS and BDRS-DL scores
at baseline than did the subjects who had AD at
follow-up. The frequency of the apoE-e4 allele or
the frequency of depression at baseline was not
dierent between the three groups.
Predictors for reversible memory impairment in
the multivariate analysis were evaluated by com-
paring group I (reversible memory impairment) in
Table 2 with group II (memory impairment at
follow-up) and group III (AD at follow-up). The
variables age, baseline delayed recall score, and
baseline BDRS-DL score were retained in the
model after backward step selection (Table 3). The
BDRS-DL score was associated with reversibility
in the unexpected direction. The sensitivity of the
model was 58%, the specificity 74%, the positive
predictive value (PPV) (i.e. the chance that subjects
with a predicted probability for reversible memory
impairment larger than 0.50 had reversible memory
impairment) was 60%, and the negative predictive
value (NPV) (the chance that subjects with a
predicted probability for reversible memory
impairment lower than 0.50 did not have reversible
memory impairment) was 73%. Since the accuracy
of the analysis could have been influenced by the
fact that not all subjects completed the 5-year
follow-up, we repeated the logistic regression
analysis with subjects with only a 5-year follow-
up. The variables age, baseline delayed recall score,
baseline BDRS-DL score, and baseline MMSE
Fig. 1. Course of memory impairment. Note that subjects who had AD at the 2-year follow-up were considered to have a 5-year
follow-up if the baseline assessment of these subjects was at least 5 years ago
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Table 2. Baseline characteristics and follow-up scores according to outcome at the latest available follow-up
assessment
Outcome at follow-up
No memory
impairment
Memory impairment
Not demented AD p-Value
Group I Group II Group III I vs II I vs III II vs III
(N  26) (N  18) (N  19)
Age 55.2 (6.9) 57.9 (11.3) 69.0 (7.9) 0.33 50.001 0.001
Range 40–68 40–77 48–81
Age below 65/above 65 (% below 65) 24/2 (92) 12/6 (67) 4/15 (21) 0.08 50.001 0.01
Education (years) 9.7 (2.8) 11.2 (2.6) 10.3 (3.6) 0.08 0.57 0.38
Sex male/female 16/10 10/8 8/11 0.93 0.32 0.62
APO-e4/APO-e4- (%e4) 8/11 (42) 9/8 (53) 6/2 (75) 0.75 0.25 0.54
HDRS at baseline 10.8 (6.5) 13.0 (7.0) 9.7 (5.3) 0.28 0.57 0.12
GDS at baseline 0.93 0.08 0.05
ÿ2 (%) 10 (38) 8 (44) 2 (11)
ÿ3 (%) 16 (62) 10 (56) 17 (89)
BDRS-DL at baseline 0.88 (0.8) 0.47 (0.47) 1.2 (0.61) 0.10 0.08 0.001
MMSE at baseline 28.0 (1.6) 27.7 (1.5) 26.5 (1.8) 0.62 0.005 0.03
MMSE (corrected) at baseline 28.0 (1.5) 27.7 (1.7) 27.2 (1.7) 0.48 0.12 0.46
MMSE (corrected) at follow-up 28.4 (1.3) 25.4 (2.5) 23.4 (5.4) 50.001 0.003 0.17
Delayed recall at baseline* ÿ1.85 (0.34) ÿ2.1 (0.53) ÿ2.2 (0.80) 0.14 0.03 0.39
Delayed recall at follow-up* ÿ0.27 (0.63) ÿ2.54 (0.73) ÿ2.32 (1.1) 50.001 50.001 0.46
Depressed/not depressed at baseline (% depressed) 8/18 (31) 9/9 (50) 5/14 (26) 0.33 1.0 0.25
Depressed{/not depressed at follow-up (% depressed) 1/25 (4) 5/12 (29) 1/14 (7) 0.03 1.0 0.18
All data are means (SD) unless specified otherwise.
*Data expressed as z-score. A z-score below zero indicates below average performance.
{ Subjects with depression at both baseline and follow-up.
Table 3. Predictors of outcome after logistic regression with backward step selection
Outcome Selected variables (OR, CI, p-value) Sensitivity Specificity PPV NPV
Reversible memory
impairment
Age (0.87, 0.8–0.9, 0.001)
Delayed recall (4.4, 1.2–16.4, 0.03)
BDRS-DL (3.2, 1.1–9.5, 0.03)
54 73 58 69
Reversible memory
impairment (only subjects
with a 5-year follow-up)
Age (0.84, 0.7–1.0, 0.01)
Delayed recall (11.3, 1.0–120, 0.05)
BDRS-DL (6.8, 0.9–3.7, 0.07)
MMSE (1.8, 0.9–52.5, 0.09)
87 76 72 89
AD Age (1.2, 1.1–1.3, 0.001)
Delayed recall (0.35, 0.1–1.2, 0.09)
MMSE (0.65, 0.4–1.0, 0.07)
74 89 74 89
AD (only subjects with a
5-year follow-up)
Age (1.3, 1.1–1.5, 0.003)
MMSE (0.40, 0.2–1.0, 0.04)
93 86 81 95
OR  odds ratio per unit change; CI  confidence interval; PPV  positive predictive value; NPV  negative predictive value.
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score were selected with backward step selection
(Table 3). Again, the BDRS-DL score was associ-
ated with reversibility in the unexpected direction.
The predictive accuracy was better than that of the
model with all subjects (Table 3).
Predictors of AD in the multivariate analysis
were evaluated by comparing group III (AD at
follow-up) in Table 2 with group I (reversible
memory impairment) and group II (memory
impairment at follow-up). The variables age, base-
line delayed recall score, and baseline MMSE score
were retained in the model after backward step
selection (Table 3). The sensitivity of the model
was 76%, the specificity 89%, the PPV 76%, and
the NPV 85%. When the analysis was repeated
with only subjects with a 5-year follow-up, the
variables age and baseline MMSE score were
retained in the model after backward step selection
and the predictive accuracy was higher than that of
the model with all subjects (Table 3).
Decision rules for identifying subjects with reversible
memory impairment and subjects with dementia at
follow-up
In order to develop decision rules that can be
easily used in clinical practice to predict outcome,
we dichotomized all variables. The cut-o points
were established such that the outcome could be
predicted with a high positive predictive value.
Twenty-two of the 26 subjects (85%) with revers-
ible memory impairment were younger than 65,
had a delayed recall score between the first and the
tenth percentile, and a corrected MMSE score
above 26.5. Also six subjects with persistent
memory impairment or AD fulfilled these criteria
(the PPV was 79%). Thirteen of the 19 subjects
(68%) with AD at follow-up were older than 65
and had a BDRS-DL score at base51. Three non-
demented subjects fulfilled these criteria (the PPV
was 81%).
The decision rules for reversible memory im-
pairment were based on corrected MMSE and
delayed recall scores. Since these corrected scores
may not be available, we also used uncorrected
scores. Fourteen of the 26 subjects (54%) with
reversible memory impairment were younger than
65 years, had a delayed recall of 54 words, and
had a MMSE score 528. Four subjects with
persistent memory impairment or AD at follow-up
fulfilled these criteria (the PPV was 78%).
DISCUSSION
The main conclusion of this study is that objective
memory impairment in non-demented subjects is
reversible (42%) as often as it is a precursor of
subsequent AD (39%). Age and the baseline
MMSE and delayed recall scores were the best
predictors of outcome.
Our study is unique for several reasons. First,
there have been no previous longitudinal studies
that focused on the prediction of reversible
memory impairment. Second, we followed
memory-impaired subjects for up to 5 years,
which is longer than in most other studies. Third,
we also included younger subjects in the age range
40–60 years, which enables us to generalize the
results more than in other studies. Fourth, we
investigated not only cognitive measures and age as
predictors but also a functional measure, a genetic
marker, and the presence of depression.
This is the first study that shows that in a clinical
setting the severity of the memory impairment, age,
a low score on the MMSE, and the degree of
functional impairment are associated with an
increased risk of AD in non-demented elderly
subjects with memory impairment. These findings
corroborate the findings from population-based
studies (Braekhus et al., 1995; Brayne et al., 1997;
Jacobs et al., 1995; Linn et al., 1995; Ott et al.,
1998). The findings that functional impairment was
associated with reversibility of memory impairment
in the wrong direction in the multivariate analysis
probably resulted from the fact that the BDRS-DL
score tended to be lower in subjects with persistent
memory impairment than in subjects with revers-
ible memory impairment (Table 2). The relation
between depression and the outcome of memory
impairment was not straightforward. In one third
of the subjects who were depressed at baseline, the
depression improved together with the memory
impairment (N  7), in one third both the depres-
sion and the memory impairment persisted at
follow-up (N  6), and in one third the depression
improved while the cognitive impairment remained
or progressed to AD (N  6). The latter group was
at baseline older than the other groups [66 years vs
55 years (p  0.04) and 56 years (p  0.15)
respectively]. Thus, when both moderately severe
depression and memory impairment are present,
the memory impairment is not necessarily second-
ary to the depression, and this is probably
especially true in elderly subjects (O’Connor et al.,
1990). We expected that the apoE-e4 allele would
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be strongly related with AD or persistent memory
impairment. However, a substantial number of the
subjects with reversible memory impairment
appeared to be carriers of the apoE-e4 allele. All
these subjects were younger than 65 years. This
finding is of interest because it suggests that only in
subjects older than 65 is the apoE-e4 allele asso-
ciated with persistent memory impairment or AD
(Coria et al., 1995; Petersen et al., 1995). The
apoE-e4 allele was frequently found in subjects
who developed dementia at follow-up, but the
apoE-e4 allele frequency in the demented subjects
was not significantly dierent from that of the
other subjects, probably because the apoE geno-
type was not determined in all demented subjects.
In almost 50% of the subjects with reversible
memory impairment, the improvement of cognitive
functioning may have resulted from improvement
of depression. In the other subjects, the improve-
ment could be due to improvement of subsyndro-
mal depression or stress, that was caused, for
example, by bereavement, co-morbid disorders, or
pain. We did not, however, investigate these
possible causes of reversible memory impairment.
In addition, improvement could also have resulted
from learning eects or regression to the mean.
Nineteen per cent of the subjects continued to have
memory impairment after 5 years but had not
developed AD. These subjects were relatively
young and had little functional impairment at
baseline. Depression was common at baseline and
persisted in more than 50% of the subjects. This
may indicate that in these subjects the memory
impairment is related to depression, but it can not
be excluded that these subjects would develop AD
later on. The apoE-e4 allele frequency was high,
suggesting that some of the subjects would develop
AD after the follow-up period. In AD, severe
memory impairment can exist up to 13 years before
other cognitive deficits develop (Didic et al., 1998).
In order to translate these findings to clinical
practice, we tried to formulate some decision rules.
Clearly, these rules need cross-validation in our
own population and in dierent settings. The
decision rules were not based on the same variables
that were selected by the multivariate analyses.
This probably resulted from the fact that we made
use of dichotomized scores in formulating the
decision rules. One of the most important factors in
predicting outcome was age. Typically, subjects
with reversible memory impairment were younger
than 65 years and subjects with AD at follow-up
were older than 65 years. When subjects older than
65 years also experienced diculties with activities
of daily living there was a high risk (81%) of
subsequent AD. The combination of age below 65,
a delayed recall of 54 words, and a MMSE score
528 indicated a high chance (78%) that the
memory impairment was reversible. The sensitivity
of these decision rules was low (less than 70%),
which means that the baseline characteristics of
subjects with reversible memory impairment or AD
at follow-up are heterogeneous. This lack of a
simple profile of subjects with reversible memory
impairment or AD at follow-up implies that
information from dierent sources is important
to predict outcome. The sensitivity and positive
preictive value may be further increased by
using biological markers of AD, such as hippo-
campal atrophy (de Leon et al., 1993; Visser et al.,
1999).
A limitation of the study is the fact that not all
subjects completed the 5-year follow-up. The
reason why not all subjects had a 5-year follow-
up was that not all subjects were long enough in the
study. As can be seen in Fig. 1, the outcome of
some subjects who had memory impairments but
who were not demented after 2 years changed after
5 years. We therefore repeated the analyses with
only subjects with 5-year follow-up data. This had
the disadvantage that there were few subjects. The
outcome of the logistic regression model and the
decision rules are sample-dependent and may
therefore not apply in other settings. There may
be other causes of reversible memory impairment
such as medications, hypothyroid or hyperthyroid
function, or vitamin deficiency, but these con-
ditions were excluded at baseline.
CONCLUSION
Memory impairment is often reversible, and for
this reason memory impairment alone is not
sucient cause to consider a subject as preclinically
demented. Predictive accuracy can be increased by
taking into consideration simple measures such as
age, the scores on the MMSE and delayed recall,
and the degree of functional impairment. When
both depression and memory impairment are
present, the memory impairment is not necessarily
secondary to the depression, but both can be the
first symptoms of AD. Memory impairment may
even be reversible in carriers of the apoE-e4
allele.
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